Hospital Acquired Infections Therapeutics Market Size

Hospital Acquired Infections Therapeutics Market Size

The global hospital acquired infections therapeutics market size was valued at USD 12.5 billion in 2023 and is expected to exhibit growth at a CAGR of 3.2% from 2024 – 2032. The progression of the industry is attributed to increasing prevalence of healthcare acquired infections, increasing emphasis on better patient care, and active government involvement in containing hospital acquired infections.

To get key market trends

  Download Free Sample

The prevalence of HAIs is rising due to factors such as increased hospital admissions, longer hospital stays, and the growing use of invasive devices. These infections, including urinary tract infections, pneumonia, and bloodstream infections, are driving the demand for effective therapeutic interventions. The increasing number of immunocompromised patients also contributes to the rise in HAIs.
 

The development of new and more effective antimicrobial therapies, including antibiotics and antifungals, is a key driver of the HAI therapeutics market. Pharmaceutical companies are investing heavily in research and development to combat antibiotic-resistant strains of bacteria. The availability of advanced therapeutics tailored to specific pathogens and infection types is improving patient outcomes and driving industry progression.
 

Hospital acquired infections therapeutics refers to a range of medical treatments designed to prevent, control, and treat infections acquired during hospital stays, often resistant to standard antimicrobial therapies.